NCT00623558
Completed
Phase 2
A Randomized, Multicenter, Open Phase II Study of Cetuximab With Docetaxel, Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
ConditionsHead and Neck Neoplasm
Overview
- Phase
- Phase 2
- Intervention
- Docetaxel
- Conditions
- Head and Neck Neoplasm
- Sponsor
- Seoul National University Hospital
- Enrollment
- 92
- Locations
- 1
- Primary Endpoint
- Response rate
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
The aim of the study is to investigate the efficacy and safety of cetuximab, docetaxel, cisplatin combination as induction therapy in locally advanced head and neck squamous cell carcinoma.
Investigators
Dae Seog Heo
Professor
Seoul National University Hospital
Eligibility Criteria
Inclusion Criteria
- •Unresectable, locally advanced (cT4b \&/or cN2-3) HNSCC
- •ECOG performance status 0-1
- •Age 18 or older than 18 years
- •Measurable disease by RECIST criteria
- •Having signed informed consent
- •ALT and AST\<2.5 times ULN
- •Serum albumin level ≥3.0g/dL
- •Serum AKP \< 2.5 times ULN
- •Bilirubin level \< 1.5mg/dL
- •Serum creatinine \<1.5 times ULN
Exclusion Criteria
- •Previous cytotoxic chemotherapy for HNSCC
- •Radiotherapy for targeted lesions within six months
- •Previous EGFR pathway-targeting therapy
- •Prior surgery for cancer (excluding diagnostic biopsy within 4 weeks prior to study entry)
- •Distant metastatic disease
- •Heart failure, coronary artery disease, myocardial infarction within the last 6 months
- •Known allergy to any study treatment
- •Pregnancy or lactation period
- •Any investigational agent within the past 28 days
- •Other previous malignancy within 5 year, except adequately treated in situ cervical cancer, or non-melanoma skin cancer
Arms & Interventions
1
Docetaxel+CDDP
Intervention: Docetaxel
1
Docetaxel+CDDP
Intervention: Cisplatin
2
Docetaxel+CDDP+Cetuximab
Intervention: Cetuximab
2
Docetaxel+CDDP+Cetuximab
Intervention: Docetaxel
2
Docetaxel+CDDP+Cetuximab
Intervention: Cisplatin
Outcomes
Primary Outcomes
Response rate
Time Frame: after induction treatment
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 2
Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract CancerResectable Biliary Tract CancerNCT05640791Tianjin Medical University Cancer Institute and Hospital40
Completed
Phase 2
Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNNSquamous Cell Carcinoma of the Hypopharynx Stage IIISquamous Cell Carcinoma of the Hypopharynx Stage IVSquamous Cell Carcinoma of the Larynx Stage IIISquamous Cell Carcinoma of the Larynx Stage IVSquamous Cell Carcinoma of the Oropharynx Stage IIISquamous Cell Carcinoma of the Oropharynx Stage IVSquamous Cell Carcinoma of the Oral Cavity Stage IIISquamous Cell Carcinoma of the Oral Cavity Stage IVNCT01884259Arbeitsgemeinschaft medikamentoese Tumortherapie100
Completed
Phase 2
Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell CancerMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell CarcinomaRecurrent Metastatic Squamous Neck Cancer With Occult PrimaryRecurrent Salivary Gland CancerRecurrent Squamous Cell Carcinoma of the HypopharynxRecurrent Squamous Cell Carcinoma of the LarynxRecurrent Squamous Cell Carcinoma of the Lip and Oral CavityRecurrent Squamous Cell Carcinoma of the NasopharynxRecurrent Squamous Cell Carcinoma of the OropharynxRecurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityRecurrent Verrucous Carcinoma of the LarynxRecurrent Verrucous Carcinoma of the Oral CavitySalivary Gland Squamous Cell CarcinomaStage IV Salivary Gland CancerStage IV Squamous Cell Carcinoma of the HypopharynxStage IV Squamous Cell Carcinoma of the LarynxStage IV Squamous Cell Carcinoma of the Lip and Oral CavityStage IV Squamous Cell Carcinoma of the NasopharynxStage IV Squamous Cell Carcinoma of the OropharynxStage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityStage IV Verrucous Carcinoma of the LarynxStage IV Verrucous Carcinoma of the Oral CavityTongue CancerUntreated Metastatic Squamous Neck Cancer With Occult PrimaryNCT01316757Fox Chase Cancer Center24
Completed
Phase 2
Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerNCT00097227Eli Lilly and Company165
Terminated
Phase 2
Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung CancerRecurrent Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung CancerNCT00976677National Cancer Institute (NCI)10